Page last updated: 2024-12-05

3,4-dimethoxyamphetamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-dimethoxyamphetamine: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8423
CHEMBL ID277540
SCHEMBL ID266195
MeSH IDM0063037

Synonyms (46)

Synonym
3,4-dimethoxy-alpha-methylphenethylamine
phenethylamine, 3,4-dimethoxy-alpha-methyl-
3,4-dimethoxyamphetamine
alpha-methylhomoveratrylamine
benzeneethanamine, 3,4-dimethoxy-alpha-methyl-
einecs 204-383-7
1-(3,4-dimethoxyphenyl)-2-aminopropane
3,4-dimethoxyphenylisopropylamine
benzenethanamine, 3,4-dimethoxy-.alpha.-methyl-
benzeneethanamine, 3,4-dimethoxy-.alpha.-methyl-
NCIOPEN2_006035
AKOS000162251
1-(3,4-dimethoxyphenyl)propan-2-amine
CHEMBL277540 ,
(+/-)2-(3,4-dimethoxy-phenyl)-1-methyl-ethylamine
bdbm50024201
2-(3,4-dimethoxy-phenyl)-1-methyl-ethylamine(3,4-dma)
2-(3,4-dimethoxy-phenyl)-1-methyl-ethylamine
120-26-3
A804477
unii-emh5pub78v
emh5pub78v ,
AKOS017269683
SCHEMBL266195
2-(3,4-dimethoxyphenyl)-1-methylethylamine
1-(3,4-dimethoxy-phenyl)-prop-2-ylamine
2-(3,4-dimethoxyphenyl)-alphamethylethylamine
3-(3,4-dimethoxyphenyl)-2-aminopropane
alpha-methyl-3,4-dimethoxyphenethylamine
3-(3,4-dimethoxyphenyl)-2-propylamine
1-(3,4-dimethoxyphenyl)-2-propanamine #
phenethylamine, 3,4-dimethoxy-.alpha.-methyl-
3,4-dimethoxy-.alpha.-methylphenethylamine
.alpha.-methylhomoveratrylamine
(+/-)-3,4-dimethoxyamphetamine
(+/-)-1-(3,4-dimethoxyphenyl)-2-aminopropane
2-amino-1-(3',4'-dimethoxyphenyl)propane
1-(3,4-dimethoxyphenyl)-2-propylamine
3,4-dma
DTXSID50902787
Q27277248
1-(3,4-dimethoxyphenyl)-2-propanamine
SY268200
mfcd01708303
(s)-1-(3,4-dimethoxyphenyl)2-propanamine
PD044364
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki43.30000.00020.667710.0000AID5270
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki43.30000.00010.601710.0000AID5270
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki64.60000.00010.739610.0000AID3695
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki64.60000.00031.29679.2440AID3695
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Ki64.60000.00101.67479.2000AID3695
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Ki64.60000.00101.67479.2000AID3695
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki43.30000.00020.590910.0000AID5270
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Kd3.54810.00042.58328.5114AID6406
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Kd3.54810.00012.62198.5114AID6406
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd3.54810.00012.29338.5114AID6406
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Kd3.54810.02342.74218.5114AID6406
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Kd3.54810.02342.74218.5114AID6406
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Kd3.54810.02342.74218.5114AID6406
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd3.54810.00042.47358.5114AID6406
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)Kd3.54810.02342.74218.5114AID6406
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Kd3.54810.00012.70068.5114AID6406
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)Kd3.54810.02342.74218.5114AID6406
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)Kd3.54810.02342.74218.5114AID6406
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Kd3.54810.00082.62148.5114AID6406
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)Kd3.54810.02342.74218.5114AID6406
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Kd3.54810.00082.62148.5114AID6406
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID241440Inhibitory concentration against monoamine oxidase A in rat brain mitochondrial suspension2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling.
AID6406Affinity against 5-hydroxytryptamine receptors in rat fundus model1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Serotonin receptor affinities of psychoactive phenalkylamine analogues.
AID227926Equilibrium constant for DNB complex formation1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID88883Hallucinogenic activity i.e; ratio of effective dose of mescaline to the effective dose in human1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID23503Partition coefficient (logP)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID5270Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID90250Human hallucinogenic activity relative to mescaline1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID3695Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID167866Hyperthermic potency in rabbit relative to DOM1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID19263Log value of hallucinogenic activity was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID5797Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID1131957Hallucinogenic activity in human relative to mescaline1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Structure-activity studies on hallucinogenic amphetamines using molecular connectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (54.55)18.7374
1990's1 (9.09)18.2507
2000's3 (27.27)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.53 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies1 (7.69%)4.05%
Observational0 (0.00%)0.25%
Other11 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]